---
title: "Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Clinical evidence"
description: "Formulary evidence on Emiltatug ledadotin (Emi-Le, XMT-1660) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Clinical evidence. Covers EMBLEM-1 and MER-XMT-1660-1 phase 1 dose escalation and backfill. 73 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/clinical-evidence"
published: "2026-09-17T22:01:26-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 EMBLEM-1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Registered objective of the phase 2 part

> “The third part, the Phase 2 part of the trial, called EMBLEM-1, will find out if Emi-Le works to treat aggressive Adenoid Cystic Carcinoma and continue to check how safe Emi-Le is.”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.1-2"></a>

###### Sponsor-stated purpose of the phase 2 study

> “These encouraging data at ASCO indicate strong promise to support a population distinctly in need of effective therapies and will help inform the pivotal Phase 2 study we will undertake in a larger set of participants.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status: registry record for the full phase 1/2 protocol

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2022-08-15” |
| Primary completion (estimated) | “2027-02” |
| Study completion (estimated) | “2027-12” |
| Recruitment status | “Recruiting” |
| Last update posted | “2026-06-29” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.2-2"></a>

###### Registered sites

> “This study has 26 locations”
> “United States”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.2-3"></a>

###### Enrollment status of the phase 2 part

> “The phase 2 EMBLEM-1 study (NCT05377996), a continuation of the phase 1 program, is enrolling patients with aggressive ACC and measurable disease per RECIST v1.1”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.1.2-4"></a>

###### EMBLEM-1 start date and site list specific to the phase 2 part

No evidence found.

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Phase 1/2, single-group, open-label design with three parts

> “A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors”
> “The study will have three parts. The first part called Dose Escalation, will find out how much Emi-Le should be given to participants. The second part called Dose Expansion, will use the dose found in the first part to find out how safe Emi-Le is and if it works to treat solid tumors.”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

| Design feature | Registry record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.3-2"></a>

###### Planned registrational pathway

> “The objective of the Phase 1b study is to define an optimized dose and to define clinical activity in one or more histologically defined tumor types for a potential single-arm registrational trial for accelerated approval or randomized trial.”

Source: [Day One Biopharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1845337/000119312526066956/dawn-20251231.htm)

<a id="topic-3.1.1.3-3"></a>

###### Contingent value right milestone tied to a registrational ACC-1 trial

> “$4.00 per CVR, payable upon occurrence of the first dosing of the first participant in a Registrational Clinical Trial (as defined in the CVR Agreement) of Emi-Le for adenoid cystic carcinoma type 1 (“ACC-1”) on or before December 31, 2027;”

Source: [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-3.1.1.3-4"></a>

###### Tissue submission for biomarker testing

> “Tissue is submitted for B7-H4 testing and molecular profiling.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Aggressive ACC definition for EMBLEM-1

> “The phase 2 EMBLEM-1 study (NCT05377996), a continuation of the phase 1 program, is enrolling patients with aggressive ACC and measurable disease per RECIST v1.1, with the phenotype confirmed by both histopathologic criteria (solid/basaloid histology or HGT) and clinical phenotype (progression within 3 years or extrapulmonary metastasis).”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.1.4-2"></a>

###### Key inclusion criteria: registry record for all study parts

| Criterion | Quoted registry text |
| --- | --- |
| Disease | “Recurrent or advanced solid tumor and has disease” |
| Performance status | “Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1” |
| Tumor tissue | “Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically contraindicated, prior to Cycle 1 Day 1” |
| Age | “18 Years and older” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.4-3"></a>

###### Key exclusion criteria: registry record for all study parts

> “Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.”
> “Prior B7-H4 targeted treatment.”
> “Untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.”
> “History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver diseases.”
> “Clinically significant cardiovascular disease”
> “Active keratitis (inflammation of the cornea of the eye)”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.4-4"></a>

###### ACC-specific eligibility criteria in the registry record

No evidence found.

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### EMBLEM-1 dosing regimen

> “The dosing regimen is emiltatug ledadotin 80 mg/m² (capped at 160 mg) Q4W, with ORR as the primary end point and DOR, DCR, PFS, overall survival, and safety as secondary end points.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.1.5-2"></a>

###### Registered intervention

> “Single arm Emi-Le alone (monotherapy)”
> “Emi-Le will be administered through a vein in your arm or port catheter (intravenously)”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using RECIST v1.1 Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Registered primary outcome for EMBLEM-1

| Outcome measure | Description | Time frame |
| --- | --- | --- |
| “Objective Response Rate (ORR) (Dose Expansion and EMBLEM-1)” | “The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1” | “approximately 3 years” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.6.1-2"></a>

###### Registered secondary outcomes for EMBLEM-1

| Outcome measure | Description | Time frame |
| --- | --- | --- |
| “Duration of response (DOR) (Dose Escalation, Dose Expansion, and EMBLEM-1)” | “The time from when response criteria are first met until disease progression or death in participants who achieve a complete or partial response” | “Up to approximately 3 years” |
| “Progression-free survival (PFS) (EMBLEM-1)” | “The time from the date of first dose of study treatment until the first date at which disease progression is objectively documented or date of death due to any cause, whichever occurs first” | “Up to approximately 3 years” |
| “Assess the overall survival (OS) of patients treated with Emi-Le (Dose Escalation, Dose Expansion, and EMBLEM-1)” | “The time from the date of first dose of study treatment to the date of death due to any cause” | “Up to approximately 3 years” |
| “Incidence of adverse events (EMBLEM-1)” | “Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose” | “3 years” |
| “Antidrug antibodies (ADAs) and neutralizing antibodies (NAbs) (Dose Escalation, Dose Expansion, and EMBLEM-1)” | “Assess the development of ADAs and NAbs to Emi-Le” | “Up to approximately 3 years” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.6.1-3"></a>

###### Regulatory basis for ORR in single-arm studies

> “When defined in this manner, ORR is a direct measure of a drug antitumor activity, which can be evaluated in a single-arm study.”
> “The significance of ORR is assessed by its magnitude and duration, and the percentage of CRs.”
> “In settings where there is no available therapy and where major tumor regressions can be presumed to be attributed to the tested drug, the FDA has sometimes accepted ORR and response duration observed in single-arm studies as substantial evidence supporting accelerated approval.”
> “Single-arm trials do not adequately characterize time-to-event endpoints such as overall survival, DFS (and EFS), TTP, or PFS.”

Source: [FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics guidance (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-4"></a>

###### Absence of approved therapy and historical outcomes in aggressive ACC

> “About 40% of patients (pts) have an aggressive form of ACC (referred to as ACC-I; Ferrarotto et al., Clin Cancer Res 2021) characterized by solid/basaloid or high-grade transformation histology and poor prognosis with median progression-free survival (PFS) of 2–3 months and median overall survival (OS) of approximately 3 years. There are no approved systemic therapies for recurrent or metastatic ACC.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.1.6.1-5"></a>

###### Sponsor-stated rationale for selecting ORR in EMBLEM-1

No evidence found.

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment: registry record for all study parts

| Enrollment type | Participants |
| --- | --- |
| Estimated | “360” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment specific to EMBLEM-1

No evidence found.

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

EMBLEM-1 is the phase 2 part of the NCT05377996 protocol and had reported no results as of the June 29, 2026 registry update. Public information on the design comes from the registry record, which covers all three study parts, and from a conference report of the ASCO 2026 presentation. The planned EMBLEM-1 sample size, the prespecified ORR threshold, the use of blinded independent central review, and the statistical analysis plan are not public; the registry lists investigator-assessed ORR and an estimated enrollment of 360 participants for the entire phase 1/2 study. The single-arm design without a comparator means time-to-event outcomes such as PFS and OS cannot be attributed to treatment, a limitation noted in FDA endpoint guidance. Eligibility requires both a histopathologic phenotype (solid/basaloid histology or high-grade transformation) and a clinical phenotype, which matches the population in the May 2026 FDA breakthrough therapy designation, so results would not apply to non-aggressive ACC. The registry exclusion criteria remove participants with prior auristatin-based or B7-H4-targeted therapy, untreated CNS metastases, clinically significant liver or cardiovascular disease, and active keratitis.

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics guidance (2018)](https://www.fda.gov/media/71195/download); [Servier breakthrough therapy designation announcement (2026)](https://servier.mediaroom.com/2026-05-12-Emiltatug-Ledadotin-Emi-Le-Granted-Breakthrough-Therapy-Designation-by-the-U-S-FDA-for-Adenoid-Cystic-Carcinoma-ACC)

<a id="heading-3.1.2"></a>

#### 3.1.2 MER-XMT-1660-1 Phase 1 Dose Escalation and Backfill

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registered objective

> “This first-in-human (FIH) study will test the safety, side effects, and antitumor activity of a drug called Emi-Le ((Emiltatug Ledadotin, formerly XMT-1660).”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.2.1-2"></a>

###### Objectives of the ACC interim analysis

> “Here we report antitumor activity results from the Phase 1 ACC-specific dose escalation/backfill cohort, along with safety data for all enrolled pts (NCT05377996).”
> “Primary objectives included safety and preliminary antitumor activity.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and registered sites

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2022-08-15” |
| Primary completion (estimated) | “2027-02” |
| Study completion (estimated) | “2027-12” |
| Number of locations | “This study has 26 locations” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.2.2-2"></a>

###### Data cut-off dates of interim ACC analyses

> “As of December 13, 2024, 130 pts were dosed.”

Source: [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009)

> “The presentation will focus on Emi-Le’s Phase 1 dose escalation and backfill cohorts as of a March 8, 2025 data cut-off”

Source: [Mersana Therapeutics ASCO 2025 announcement (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925055240/tm2516680d1_ex99-1.htm)

> “As of October 1, 2025, 221 pts were dosed.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.2-3"></a>

###### Presentation of the ASCO 2026 analysis

> “Day One Biopharmaceuticals, now part of Servier Group, will also share results from an ongoing Phase 1 trial evaluating investigational compound Emi-Le (emiltatug ledadotin) in an oral presentation on June 1 at 8:24 a.m. CDT.”

Source: [Servier ASCO 2026 presentations announcement (2026)](https://servier.mediaroom.com/2026-05-21-Servier-Presentations-at-ASCO-2026-Spotlight-Expanding-Rare-Oncology-Portfolio)

<a id="topic-3.1.2.2-4"></a>

###### Data cut-off date of the ASCO 2026 oral presentation

No evidence found.

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Dose escalation with parallel backfill cohorts

> “In parallel with DES, backfill cohorts are enrolling additional participants at multiple dose levels”
> “Each backfill cohort is enrolling up to 12 patients and may focus on tumor types of particular interest”
> “Data from both DES and backfill cohorts will be utilized to determine the RP2D”

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.3-2"></a>

###### Tumor cohorts, B7-H4 assessment, and dose expansion regimens

> “The phase 1 study enrolled patients with recurrent, advanced, or metastatic solid tumor cohorts, including triple-negative breast cancer, hormone receptor–positive/HER2-negative breast cancer, endometrial cancer, ovarian cancer, and ACC-I. Patients are aged 18 years or older with an ECOG performance status of 0 or 1 and B7-H4 expression assessed retrospectively by immunohistochemistry.”
> “The expansion phase, which is enrolling patients with TNBC and ACC-I, evaluates 67.4 mg/m² every 4 weeks (Q4W), a 44.5-mg/m² split-dose lead-in followed by 80 mg/m² Q4W, and 80 mg/m² Q4W. ORR, safety, and tolerability serve as primary end points.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.3-3"></a>

###### Post hoc analysis in clinicopathologically defined aggressive ACC

> “Further, a post-hoc analysis was conducted in a more clearly defined aggressive ACC subtype reflecting clinical features used in practice by clinicians and pathologists, including solid histology or high-grade transformation.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

> “For the post hoc analysis, a stricter clinicopathologic definition required both a histopathologic phenotype (solid/basaloid histology or HGT) and at least one clinical risk factor (progression within 3 years or extrapulmonary metastasis).”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### ACC-specific eligibility in the dose escalation and backfill cohorts

> “Eligibility criteria for ACC pts required features consistent with aggressive disease that included 1 of the following: 1) clinically aggressive phenotype, defined as < 3 years to recurrence/progression or de novo metastatic disease with atypical metastatic sites and solid tumor morphology, and/or 2) molecular features consistent with poor prognosis (activating NOTCH1–4 mutations or c-Myc positive or p63 negative/low per IHC).”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.4-2"></a>

###### ACC-specific eligibility as described at ASCO 2026

> “Patients with ACC were required to have the following features: a histopathologic phenotype (solid tumor morphology), a clinical phenotype (less than 3 years to recurrence/progression or de novo metastatic disease with atypical sites), and/or activating NOTCH1-4 mutations, c-Myc positivity, or negative/low p63.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.4-3"></a>

###### Key registry inclusion and exclusion criteria

> “Recurrent or advanced solid tumor and has disease”
> “Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1”
> “Participants in DES must have at least one measurable disease (target) lesion as defined by RECIST version 1.1.”
> “Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.”
> “Prior B7-H4 targeted treatment.”
> “Active keratitis (inflammation of the cornea of the eye)”

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Dose range across all tumor types and in participants with ACC

> “Across dose escalation and backfill, eligible pts received Emi-Le at doses of 7.2–115 mg/m2 IV per Q3W or Q4W cycle. Pts with ACC received Emi-Le at doses of 57.4–89 mg/m2 IV per Q3W or Q4W cycle.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.5-2"></a>

###### Dose selection for further development

> “We landed on 80 mg/m2 monthly as the preferred dose,”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.5-3"></a>

###### Administration

> “Hanna detailed the protocol of administering the drug as a monthly intravenous infusion to evaluate its safety, tolerability, and overall efficacy within this patient population during the phase 1 trial.”

Source: [OncLive Hanna interview (2026)](https://www.onclive.com/view/dr-hanna-on-the-safety-and-efficacy-of-emi-le-in-aggressive-acc)

<a id="topic-3.1.2.5-4"></a>

###### Doses and schedules as of December 13, 2024

> “Broad range of doses and multiple dosing schedules investigated Phase 1 Dose Escalation and Backfill Enrollment”
> “130 patients dosed as of December 13, 2024 data cutoff”
> “Expansion initiated at 67.4 mg/m 2 Q4W in TNBC post - topo - 1 ADC; continuing dose exploration in High Dose Range”

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.5-5"></a>

###### Proteinuria management amendment

> “After a protocol amendment introduced an updated monitoring and management plan, including renal-protective medications, proteinuria-related dose reductions decreased from 38.9% to 20% and delays from 50.0% to 6.7% among patients with ACC.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Dose-limiting Toxicities, Adverse Events, and RECIST v1.1 Objective Response Rate as the Primary Endpoints

<a id="topic-3.1.2.6.1-1"></a>

###### Registered primary outcomes for dose escalation and expansion

| Outcome measure | Description | Time frame |
| --- | --- | --- |
| “Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with Emi-Le during the first cycle of treatment (Dose Escalation)” | “Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Emi-Le” | “17 months” |
| “Incidence of adverse events (Dose Escalation and Dose Expansion)” | “Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose” | “3 years” |
| “Objective Response Rate (ORR) (Dose Expansion and EMBLEM-1)” | “The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1” | “approximately 3 years” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.2.6.1-2"></a>

###### Registered secondary outcomes for dose escalation

| Outcome measure | Time frame |
| --- | --- |
| “Objective Response Rate (ORR) (Dose Escalation)” | “Up to approximately 3 years” |
| “Duration of response (DOR) (Dose Escalation, Dose Expansion, and EMBLEM-1)” | “Up to approximately 3 years” |
| “Maximum observed plasma concentration of Emi-Le and payload (Cmax) (Dose Escalation and Dose Expansion)” | “Up to approximately 3 years” |
| “Area under the concentration-time curve of Emi-Le and payload (AUC) (Dose Escalation and Dose Expansion)” | “Up to approximately 3 years” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.2.6.1-3"></a>

###### Endpoints of dose escalation and backfill cohorts as presented by the sponsor

> “Dose Escalation (DES) Primary Endpoints MTD , s afety and tolerability Secondary Endpoints ORR, DOR , DCR, PK, ADA Backfill Cohorts Primary Endpoint Safety and tolerability Secondary Endpoints ORR, DOR, DCR, PK, ADA”

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.6.1-4"></a>

###### Regulatory context for ORR as a measure of antitumor activity

> “When defined in this manner, ORR is a direct measure of a drug antitumor activity, which can be evaluated in a single-arm study.”
> “Stable disease should not be a component of ORR.”

Source: [FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics guidance (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.2.6.1-5"></a>

###### Historical comparator for PFS in aggressive ACC

> “With no approved therapies, median PFS and median overall survival for patients with ACC-1 are reported to be 2-3 months and 2-3 years, respectively.”

Source: [Mersana Therapeutics ASCO 2025 announcement (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925055240/tm2516680d1_ex99-1.htm)

> “About 40% of patients (pts) have an aggressive form of ACC (referred to as ACC-I; Ferrarotto et al., Clin Cancer Res 2021) characterized by solid/basaloid or high-grade transformation histology and poor prognosis with median progression-free survival (PFS) of 2–3 months and median overall survival (OS) of approximately 3 years.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Summary: participant counts differ between the ASCO 2026 abstract and oral presentation

The ASCO 2026 abstract (data cut-off October 1, 2025) reports 221 participants dosed, 35 with ACC, and 25 evaluable participants with ACC. The oral presentation at the same meeting reports 180 participants in the dose escalation and backfill cohorts, 48 with ACC, 45 evaluable participants with ACC, and 32 evaluable participants in the post hoc aggressive ACC subset. The accessible sources do not state the data cut-off of the oral presentation and do not explain why the total count is lower (180 compared with 221) while the ACC count is higher (48 compared with 35).

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-3.1.2.7.1-2"></a>

###### Planned enrollment: registry record for all study parts

| Enrollment type | Participants |
| --- | --- |
| Estimated | “360” |

Source: [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants with ACC by data cut-off: December 13, 2024

> “Total (N=130) ACC - I (N=7) Endometrial (N=12) Ovarian (N=14) HR+/HER2 - BC (N=34) TNBC 1 (N=63)”

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants with ACC by data cut-off: March 8, 2025

> “In June 2025, at ASCO, we presented interim clinical data from nine evaluable patients with ACC-1. As of October 1, 2025, we have enrolled a substantially greater number of patients with ACC-1 in these backfill cohorts than was presented at ASCO.”

Source: [Mersana Therapeutics Form 10-Q (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000162828025052202/mrsn-20250930.htm)

<a id="topic-3.1.2.7.1-5"></a>

###### Participants with ACC by data cut-off: October 1, 2025

> “As of October 1, 2025, 221 pts were dosed. Of these, 35 pts had ACC”
> “Among 25 evaluable (≥1 post-baseline scan) pts with ACC”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.7.1-6"></a>

###### Participants with ACC: ASCO 2026 oral presentation

> “As part of an ongoing Phase 1 trial, a dose escalation and backfill cohort enrolled adult patients with advanced or metastatic solid tumors (n=180), including those with ACC (n=48) defined by an aggressive clinicopathologic phenotype and/or molecular features consistent with poor prognosis.”
> “Promising signals of efficacy among 45 evaluable participants with ACC.”
> “This analysis (n=32 evaluable participants) reported promising signals:”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Efficacy-evaluable population definitions

> “Among 25 evaluable (≥1 post-baseline scan) pts with ACC”
> “For the safety set of 221 pts, Emi-Le was well tolerated with no new safety signals identified.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

> “Additionally, the following clinical activity data are being presented from evaluable patients (those with measurable disease at baseline and at least one post-baseline scan):”

Source: [Mersana Therapeutics ASCO 2025 announcement (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925055240/tm2516680d1_ex99-1.htm)

<a id="topic-3.1.2.7.2-2"></a>

###### Post hoc aggressive ACC analysis set

> “Thirteen patients were excluded; 10 patients had unavailable histology, 2 did not have clinical phenotype criteria met, and 1 did not have histopathologic phenotype criteria met. This left 35 patients with aggressive ACC, and 32 were efficacy evaluable.”
> “The preliminary analysis reported safety for all enrolled patients and antitumor activity for the ACC-specific cohort.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.7.2-3"></a>

###### Statistical methods, including confidence interval methods and censoring rules

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Derivation of the aggressive ACC subset from the ACC cohort

> “Thirteen patients were excluded; 10 patients had unavailable histology, 2 did not have clinical phenotype criteria met, and 1 did not have histopathologic phenotype criteria met. This left 35 patients with aggressive ACC, and 32 were efficacy evaluable.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.8.1-2"></a>

###### Evaluability at the October 1, 2025 data cut-off

> “Of these, 35 pts had ACC”
> “Among 25 evaluable (≥1 post-baseline scan) pts with ACC”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.8.1-3"></a>

###### Treatment discontinuation, dose reduction, and dose delay in the ACC cohort

> “In the ACC cohort (n = 48), TRAEs led to discontinuation in only 1 patient (2.1%), dose reduction in 45.8%, and dose delay in 56.3% of patients.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.8.1-4"></a>

###### Treatment duration and reasons for discontinuation other than adverse events

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Summary: reading the flattened December 2024 demographics slide

The December 13, 2024 slide lists columns in the order Total (N=130), ACC-I (N=7), endometrial (N=12), ovarian (N=14), HR+/HER2- breast cancer (N=34), and TNBC (N=63). Read in that order, the 7 participants with ACC-I had a median age of 55 years and a median of 0 prior lines of therapy (range 0 to 3), and none had received a prior topoisomerase-1 inhibitor ADC.

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.8.2-2"></a>

###### ACC cohort (n=48) and overall population (n=180): ASCO 2026 oral presentation

| Characteristic | Reported value |
| --- | --- |
| ACC: solid tumor morphology, extrapulmonary metastasis, progression within 3 years | “Among the 48 patients with ACC, 77.1% had solid tumor morphology, 77.1% had extrapulmonary metastasis, and 68.8% had progressed within 3 years of diagnosis.” |
| ACC: B7-H4 expression and NOTCH1-4 mutations | “The median B7-H4 tumor proportion score (TPS) was 77.5% (range, 2%-100%) among 40 evaluated patients, and 66.7% harbored activating NOTCH1-4 mutations.” |
| ACC: prior therapy | “Patients with ACC had received a median of 1 prior line of therapy (range, 0-3).” |
| Overall population: sex and age | “Of those in the overall population (n = 180), 88.3% were female, with a median age of 57.5 years.” |

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.8.2-3"></a>

###### ACC cohort (n=35): October 1, 2025 data cut-off

> “Of these, 35 pts had ACC, with a median of 1 prior line of therapy (range 0–3), median age 58 years, and 57% were female.”

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.8.2-4"></a>

###### ACC-I cohort (n=7): quoted demographics slide

> “Total (N=130) ACC - I (N=7) Endometrial (N=12) Ovarian (N=14) HR+/HER2 - BC (N=34) TNBC 1 (N=63) 55 55 65 61 62 48 Median age 4.5 (0 - 15) 0 (0 - 3) 2.5 (1 - 4) 5 (2 - 11) 7 (2 - 15) 4 (2 - 9) Median prior lines (range)”

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.8.2-5"></a>

###### Baseline characteristics of the post hoc aggressive ACC subset (n=35)

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Summary: ACC efficacy across interim analyses

Across four interim reports, the number of evaluable participants with ACC increased from 9 to 45. At the March 8, 2025 data cut-off, ORR was 56% (5 of 9 evaluable participants with ACC-1). At the October 1, 2025 data cut-off, ORR was 40% (10 of 25; 9 confirmed and 1 unconfirmed) and DCR was 76% (19 of 25), with median PFS not reached. In the ASCO 2026 oral presentation, ORR in all evaluable participants with ACC (n=45) was 35.6% (95% CI, 21.9% to 51.2%), DCR was 82.2%, and median DoR was 7.4 months. In the post hoc aggressive ACC subset (solid/basaloid histology or high-grade transformation plus a clinical risk factor; n=32), ORR was 46.9% (95% CI, 29.1% to 65.3%) with 1 complete response, DCR was 81.3% (95% CI, 63.6% to 92.8%), median time to response was 2.7 months, median DoR was 6.4 months (95% CI, 3.1 to 9.5), and median PFS was 7.8 months (95% CI, 4.7 to 11.6). The investigator reported that B7-H4 expression level did not clearly predict benefit. All analyses are single-arm, with investigator-assessed response, and the ORR point estimates differ by data cut-off and by population definition.

Source: [Mersana Therapeutics ASCO 2025 announcement (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925055240/tm2516680d1_ex99-1.htm); [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [OncLive Hanna interview (2026)](https://www.onclive.com/view/dr-hanna-on-the-safety-and-efficacy-of-emi-le-in-aggressive-acc); [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

<a id="topic-3.1.2.8.3-2"></a>

###### Aggressive ACC (post hoc subset) and all ACC: ASCO 2026 oral presentation

| Endpoint | Aggressive ACC, post hoc subset (n=32 evaluable) | All ACC (n=45 evaluable) |
| --- | --- | --- |
| ORR | “46.9% (95% CI, 29.1%-65.3%), which included 1 complete response (CR)” | “35.6% (95% CI, 21.9%-51.2%), which included 1 CR” |
| DCR | “81.3% (95% CI, 63.6%-92.8%)” | “82.2% (95% CI, 67.9-92.0)” |
| Median time to response | “2.7 months (95% CI, 1.4-5.3)” | Not reported |
| Median DoR | “6.4 months (95% CI, 3.1-9.5)” | “7.4 months (95% CI, 3.1-not reached)” |
| Median PFS | “7.8 months (95% CI, 4.7-11.6)” | Not reported |

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.8.3-3"></a>

###### Aggressive ACC and all ACC: sponsor announcement of the ASCO 2026 presentation

> “Promising signals of efficacy among 45 evaluable participants with ACC.”
> “Objective response rate (ORR) was 35.6%, including one complete response.”
> “Disease control rate was 82.2%.”
> “Consistent tumor shrinkage, with an ORR of 46.9%, DCR of 81.3% and median PFS of 7.8 months.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-3.1.2.8.3-4"></a>

###### Response confirmation status: conflicting descriptions of the ASCO 2026 data

> “I'm happy to say that all responses have now been confirmed, including 1 CR,”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

> “Data showed that in evaluable patients with ACC treated across all doses (n = 45), the confirmed overall response rate (cORR) and ongoing unconfirmed response rate (uPR) was 35.6% (95% CI, 21.9%-51.2%), and the median duration of response was 7.4 months (95% CI, 3.1-not reached). Post hoc data showed that for patients with aggressive ACC (n = 32), the cORR/uPR and median DOR were 46.9% (95% CI, 29.1%-65.3%) and 6.4 months (95% CI, 3.1-9.5), respectively.”

Source: [OncLive Hanna interview (2026)](https://www.onclive.com/view/dr-hanna-on-the-safety-and-efficacy-of-emi-le-in-aggressive-acc)

<a id="topic-3.1.2.8.3-5"></a>

###### Median PFS in aggressive ACC: conflicting descriptions

> “Consistent tumor shrinkage, with an ORR of 46.9%, DCR of 81.3% and median PFS of 7.8 months.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

> “Researchers also reported progression-free survival approaching eight to nine months, compared with historical expectations of approximately two months.”

Source: [CURE (2026)](https://www.curetoday.com/view/experimental-treatment-shrinks-tumors-in-rare-salivary-gland-cancer)

<a id="topic-3.1.2.8.3-6"></a>

###### Response by B7-H4 expression in ACC

> “B7-H4 expression level did not clearly predict benefit.”
> “Some patients with expression as low as 2% have evidence of durable and deep responses,”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.8.3-7"></a>

###### All ACC: October 1, 2025 data cut-off (ASCO 2026 abstract)

| Endpoint | ACC (n=25 evaluable) |
| --- | --- |
| ORR | “objective response rate was 40% (9/25 confirmed, 1/25 unconfirmed ongoing and on treatment)” |
| DCR | “disease control rate was 76% (19/25)” |
| Median PFS | “median PFS (95% CI: 13.0 weeks, not reached [NR])” |
| Median OS | “OS (95% CI: 26.6 weeks, NR) have not been reached” |

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.8.3-8"></a>

###### ACC-1: March 8, 2025 data cut-off (ASCO 2025)

> “56% ORR (5/9, including one unconfirmed response as of the March 8, 2025 data cut-off that was subsequently confirmed) in ACC-1 regardless of dose and B7-H4 expression. Among all ACC-1 patients who were enrolled in the Phase 1 clinical trial, the median progression free survival (PFS) had not yet been reached as of the March 8, 2025 data cut-off.”

Source: [Mersana Therapeutics ASCO 2025 announcement (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925055240/tm2516680d1_ex99-1.htm)

<a id="topic-3.1.2.8.3-9"></a>

###### ACC-I: December 13, 2024 data cut-off

> “Intermediate Dose Range: Encouraging Clinical Activity in Evaluable Patients With B7 - H4 High Tumors”
> “ACC-I (N=3) Ovarian (N=3) Endo (N=4) HR+BC (N=3) TNBC (N=13)”

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.8.3-10"></a>

###### Aggressive ACC and all ACC: ORR by dose level, overall survival, and independent central review

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Summary: safety across interim analyses

Safety was reported for all enrolled participants across tumor types, with limited ACC-specific detail. In the ASCO 2026 presentation (n=180), the most common TRAEs were AST increase (56%), proteinuria (54%), fatigue (42%), and nausea (33%); grade 3 AST increase occurred in 20% and grade 3 proteinuria in 23%, no grade 4 or 5 TRAEs or treatment-related deaths were reported, and 3.9% discontinued treatment for TRAEs. Any-grade TRAEs occurred in 88.9% of all participants and 100% of participants with ACC, and grade 3 TRAEs in 51.1% and 79.2%, respectively. In the ACC cohort (n=48), TRAEs led to discontinuation in 1 participant (2.1%), dose reduction in 45.8%, and dose delay in 56.3%. The ASCO 2026 abstract (safety set of 221 participants, data cut-off October 1, 2025) reports lower frequencies: proteinuria 49.8%, AST increase 49.3%, fatigue 41.2%, grade 3 AST increase and grade 3 proteinuria 17.6% each, and discontinuation for TRAEs 3.6%. At the December 13, 2024 data cut-off (n=130), frequencies were lower again (AST increase 38%, proteinuria 31%) and 5 dose-limiting toxicities were reported, with 115 mg/m2 considered a non-tolerated dose.

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009); [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.8.5-2"></a>

###### All tumor types (n=180): ASCO 2026 oral presentation, most common TRAEs

| Adverse event | Any grade | Grade 3 |
| --- | --- | --- |
| AST increase | “transient AST increase (56%)” | “transient AST increase (20%)” |
| Proteinuria | “generally asymptomatic and reversible proteinuria (54%)” | “proteinuria (23%)” |
| Fatigue | “predominantly low-grade fatigue (42%)” | Not reported |
| Nausea | “nausea (33%)” | Not reported |

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

> “The only Grade 3 TRAEs in ≥10% of pts were transient AST increase (20%) and proteinuria (23%). No Grade 4 or 5 TRAEs reported.”
> “TRAEs leading to treatment discontinuation occurred in 3.9% of patients and no treatment-related deaths were reported.”

Source: [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026)

<a id="topic-3.1.2.8.5-3"></a>

###### All tumor types and ACC cohort: ASCO 2026 oral presentation, TRAE rates by grade

> “Any-grade treatment-related adverse effects (TRAEs) occurred in 88.9% of all patients and 100% of those with ACC, and grade 3 TRAEs occurred in 51.1% and 79.2%, respectively. There were no grade 4 or 5 TRAEs and no treatment-related deaths.”
> “There was no alopecia and no interstitial lung disease or pneumonitis, and rates of cytopenias, peripheral neuropathy, keratitis, and ocular toxicity were low relative to other ADCs, according to Hanna. Neutropenia, keratitis, and neuropathy occurred in 2.2%, 3.9%, and 2.8% of all patients, respectively.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.8.5-4"></a>

###### ACC cohort (n=48): dose modifications and proteinuria

> “In the ACC cohort (n = 48), TRAEs led to discontinuation in only 1 patient (2.1%), dose reduction in 45.8%, and dose delay in 56.3% of patients. Asymptomatic proteinuria, characterized on post hoc biopsy as glomerular podocytopathy without acute renal vascular injury, represented the leading cause of dose modification.”
> “The most common TRAEs were transient aspartate aminotransferase elevations, which resolved to baseline or grade 1 by the subsequent dose, with no hepatic failure or Hy's law observed; asymptomatic and reversible proteinuria; and predominantly low-grade fatigue and nausea.”

Source: [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma)

<a id="topic-3.1.2.8.5-5"></a>

###### All tumor types (n=221): October 1, 2025 data cut-off, conflicting TRAE frequencies

| Adverse event | Reported value |
| --- | --- |
| Most common TRAEs | “proteinuria (49.8%), transient AST increase (49.3%), and fatigue (41.2%)” |
| Grade 3 TRAEs in 10% or more of participants | “transient AST increase (17.6%) and proteinuria (17.6%)” |
| TRAEs leading to discontinuation | “TRAEs leading to treatment discontinuation occurred in 3.6% of pts.” |
| Treatment-related deaths | “No treatment-related deaths were reported.” |

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010)

<a id="topic-3.1.2.8.5-6"></a>

###### All tumor types (n=130): December 13, 2024 data cut-off

| Adverse event | Reported value |
| --- | --- |
| Most common TRAEs, any grade and grade 3 | “transient AST increase (38%, G3 14%), proteinuria (31%, G3 9%), nausea (29%, G3 1%) and fatigue (28%, G3 0%)” |
| Grade 4 or 5 TRAEs | “No G4 or 5 TRAEs were reported.” |
| TRAEs leading to discontinuation | “TRAEs leading to discontinuation were observed in 2.3% of pts.” |

Source: [Hamilton et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009)

<a id="topic-3.1.2.8.5-7"></a>

###### Dose-limiting toxicities: December 13, 2024 data cut-off

> “5 DLTs observed:”
> “Three Grade 3 transient AST increases (one at 59 mg/m 2 Q4W and two at 115 mg/m 2 Q4W); 115 mg/m 2 deemed to be a non - tolerated dose”
> “One reversible Grade 3 proteinuria accompanied by peripheral oedema at 80 mg/m 2 Q4W (event confounded by concurrent gout flare)”
> “One Grade 3 pyrexia at 44.5 mg/m 2 D1+8 Q4W (self - reported and rapidly resolved)”

Source: [Mersana Therapeutics initial phase 1 data presentation (2025)](https://www.sec.gov/Archives/edgar/data/1442836/000110465925002312/tm252819d1_ex99-3.htm)

<a id="topic-3.1.2.8.5-8"></a>

###### ACC-specific TRAE frequencies by event and grade

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The ACC evidence comes from dose escalation and backfill cohorts of a first-in-human, single-arm, open-label phase 1 study without a comparator, and response was assessed by the investigator per the registry primary outcome definition; independent central review was not reported. The aggressive ACC result (ORR 46.9%, n=32) comes from a post hoc analysis in which 13 of 48 participants with ACC were excluded, 10 of them because histology was unavailable, which introduces selection risk. Participants with ACC received doses of 57.4 to 89 mg/m2 on Q3W or Q4W schedules, so results do not describe a single regimen, and the EMBLEM-1 dose (80 mg/m2 capped at 160 mg Q4W) was applied only partly in these cohorts. Reported values differ between sources: the ASCO 2026 abstract (October 1, 2025 data cut-off) reports 221 participants dosed, 35 with ACC, and ORR 40% in 25 evaluable participants, while the oral presentation reports 180 participants, 48 with ACC, and ORR 35.6% in 45 evaluable participants, and the presentation data cut-off is not stated in the accessible sources. Safety frequencies also differ (proteinuria 49.8% compared with 54%; grade 3 proteinuria 17.6% compared with 23%). Sources disagree on whether the 35.6% and 46.9% ORR include unconfirmed responses, and a patient-directed report describes PFS approaching 8 to 9 months, compared with the 7.8 months reported by the sponsor. The comparison with a historical median PFS of 2 to 3 months is an external comparison. Median follow-up, OS, ACC-specific adverse event frequencies by grade, and health-related quality of life have not been reported, the slides are not publicly available, and no peer-reviewed full publication has been identified. A protocol amendment on proteinuria management changed dose reduction and delay rates during the study, so safety outcomes before and after the amendment are not directly comparable.

Source: [Hanna et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6010); [Servier ASCO 2026 results announcement (2026)](https://servier.mediaroom.com/2026-06-01-Promising-Phase-1-Data-for-Serviers-Emiltatug-Ledadotin-Emi-Le-in-Adenoid-Cystic-Carcinoma-ACC-Presented-at-ASCO-2026); [OncLive (2026)](https://www.onclive.com/view/emiltatug-ledadotin-elicits-responses-in-aggressive-adenoid-cystic-carcinoma); [OncLive Hanna interview (2026)](https://www.onclive.com/view/dr-hanna-on-the-safety-and-efficacy-of-emi-le-in-aggressive-acc); [CURE (2026)](https://www.curetoday.com/view/experimental-treatment-shrinks-tumors-in-rare-salivary-gland-cancer); [ClinicalTrials.gov NCT05377996](https://clinicaltrials.gov/study/NCT05377996)

## Related pages
- [Emiltatug ledadotin (Emi-Le): Adenoid cystic carcinoma with solid histology or high-grade transformation](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Terms and abbreviations](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/terms-and-abbreviations.md)
- [Emiltatug ledadotin (Emi-Le): Adenoid cystic carcinoma with solid histology or high-grade transformation](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/executive-summary) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/executive-summary.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Product information and disease description](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/product-information-and-disease-description.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: Economic information and modeling report](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/economics) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/economics.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: References](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/references) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/references.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: prevalence by geography](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/prevalence) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/prevalence.md)
- [Emiltatug ledadotin (Emi-Le) in Adenoid cystic carcinoma with solid histology or high-grade transformation: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/cost-effectiveness-analyses.md)
